GH receptor polymorphisms guide second-line therapies to prevent acromegaly skeletal fragility: preliminary results of a pilot study
Our data support a predictive role of the GHR isoforms for the occurrence of i-VFs in acromegalic patients treated with second-line drugs, tailored to the individual patient. The knowledge of the GHR polymorphism may facilitate the choice of second-line therapies, improving the therapeutic approach, in the context of personalized medicine.
Authors
- Consolato Gullì (ORCID: https://orcid.org/0000-0001-6035-8774)
- Amato Infante (ORCID: https://orcid.org/0000-0003-4407-2631)
- Flavia Angelini
- Pier Paolo Mattogno (ORCID: https://orcid.org/0000-0003-2857-9096)
- Mario Rigante (ORCID: https://orcid.org/0000-0002-6111-0786)
- Alessandro Olivi (ORCID: https://orcid.org/0000-0002-4489-7564)
- Liverana Lauretti (ORCID: https://orcid.org/0000-0002-6463-055X)
- Francesco Doglietto (ORCID: https://orcid.org/0000-0002-7438-0734)
- Antonella Giampietro (ORCID: https://orcid.org/0000-0001-5756-2045)
- Flavia Costanza
- Laura De Marinis (ORCID: https://orcid.org/0000-0001-9916-0669)
- Sabrina Chiloiro (ORCID: https://orcid.org/0000-0001-9241-2392)
- Alfredo Pontecorvi (ORCID: https://orcid.org/0000-0003-0570-6865)
- Antonio Bianchi (ORCID: https://orcid.org/0000-0002-4896-5499)
Institutions
- Università Cattolica del Sacro Cuore (IT)
- Istituti di Ricovero e Cura a Carattere Scientifico (IT)
Publication Details
- Journal
- Frontiers in Endocrinology
- Published
- 2024-08-30
- DOI
- https://doi.org/10.3389/fendo.2024.1414101
- Citations
- 5
- Primary Topic
- Pituitary Gland Disorders and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 1.79
Funders
- Pfizer